Thematics Asset Management Grows Position in IQVIA Holdings Inc. $IQV

Thematics Asset Management raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 26.6% in the third quarter, Holdings Channel.com reports. The fund owned 19,631 shares of the medical research company’s stock after buying an additional 4,122 shares during the quarter. Thematics Asset Management’s holdings in IQVIA were worth $3,729,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in IQV. Physician Wealth Advisors Inc. increased its holdings in shares of IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 134 shares in the last quarter. Westside Investment Management Inc. boosted its holdings in IQVIA by 219.6% during the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after buying an additional 101 shares in the last quarter. Atlantic Union Bankshares Corp acquired a new position in IQVIA during the third quarter worth about $36,000. Root Financial Partners LLC purchased a new position in IQVIA in the third quarter valued at about $43,000. Finally, Hantz Financial Services Inc. lifted its position in shares of IQVIA by 92.0% during the 3rd quarter. Hantz Financial Services Inc. now owns 240 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 115 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Barclays raised IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective for the company in a report on Friday, March 6th. UBS Group dropped their price target on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a research note on Thursday, January 22nd. Citigroup decreased their price objective on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research report on Friday, February 6th. Finally, BMO Capital Markets set a $250.00 target price on shares of IQVIA in a report on Friday, February 6th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $229.13.

IQVIA Price Performance

Shares of NYSE:IQV opened at $164.78 on Friday. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. The business’s fifty day moving average price is $201.58 and its two-hundred day moving average price is $206.67. The stock has a market cap of $27.96 billion, a PE ratio of 20.96, a price-to-earnings-growth ratio of 1.57 and a beta of 1.39. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The company had revenue of $4.36 billion during the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.